Ixo-vec

GENETIC3 trials

Sponsors

Adverum Biotechnologies, Inc.

Conditions

Neovascular Age-Related Macular Degeneration (nAMD)Neovascular Age-Related Macular Degeneration (nAMD) Wet AMDWet AMD

Phase 2

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

RecruitingNCT07630649

Adverum Biotechnologies, Inc.Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD

Start: 2026-06-02End: 2031-06-01Target: 15Updated: 2026-08-05

Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

Active, not recruitingNCT06856577

Adverum Biotechnologies, Inc.Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD

Start: 2025-02-28End: 2030-11-23Updated: 2026-05-22

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

RecruitingNCT07482176

Adverum Biotechnologies, Inc.Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD

Start: 2026-03-16End: 2031-10-20Target: 284Updated: 2026-07-15